Intravitreous Treatment of Severe Ocular VHL Disease With Ranibizumab + E10030
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Intravitreous treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab, and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial
Clin Exp Ophthalmol 2021 Sep 21;[EPub Ahead of Print], CK Hwang, EY Chew, CA Cukras, TDL Keenan, WT Wong, WM Linehan, P Chittiboina, K Pacak, HE WileyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.